Robert Schilz, DO
-
Specialty: Pulmonary and Critical Care Medicine, Pulmonary Disease
View Expertise -
Primary Location: 11100 Euclid Ave (0 mi.)
Other Locations - Languages Spoken: English
Office Locations
UH Cleveland Medical Center Bolwell (0 mi.)
11100 Euclid Ave
Bolwell 6th Floor
Cleveland, OH 44106
216-844-8500
UH Cleveland Medical Center Mather (0 mi.)
11100 Euclid Ave
Mather Ste 1800
Cleveland, OH 44106
216-844-8500
UH Seidman Cancer Center (0 mi.)
11100 Euclid Ave
1st Floor
Cleveland, OH 44106
216-844-8500
UH Cleveland Medical Center Mather (0 mi.)
11100 Euclid Ave
Mather Ste 1800
Cleveland, OH 44106
216-844-2707
Biography: Robert Schilz, DO
Expertise
Titles
- Director, Pulmonary Vascular Disease Program, UH Cleveland Medical Center
- Associate Professor, CWRU School of Medicine
Education
Fellowship | Pulmonary/Critical Care
Pulmonary/Critical Care - Yale University School Of Medicine (1993 - 1996)
Residency | Internal Medicine/Chief Resident
Internal Medicine/Chief Resident - Cleveland Clinic (1992 - 1993)
Residency | Internal Medicine
Internal Medicine - Cleveland Clinic (1989 - 1992)
Internship | Internal Medicine
Internal Medicine - Sparrow Hospital (1988 - 1989)
Medical Education
Michigan State University College Of Human Medicine (1988)
Undergraduate
University Of Wisconsin-Madison (1979)
About
Dr. Robert Schilz is director of the Pulmonary Vascular Disease Program at University Hospitals Cleveland Medical Center. He is also an Associate Professor at Case Western Reserve University School of Medicine.
Dr. Schilz earned Doctor of Osteopathic Medicine (DO) and Doctor of Philosophy (PhD) degrees from the Michigan State University Medical Scientist Training program. He then completed a Residency and Chief Residency at the Cleveland Clinic in Cleveland, Ohio. He also completed Pulmonary & Critical Care and Research fellowships at Yale University. Prior to joining University Hospitals, Dr. Schilz was on staff at the Cleveland Clinic in Pulmonary and Critical Care Medicine.
For over 25 years, Dr. Schilz has participated in clinical and basic research in the areas of advanced lung diseases and pulmonary hypertension, with numerous publications in the areas of pulmonary hypertension, lung transplantation and advanced lung disease.
Dr. Schilz serves or has served as an advisor or committee member for a number of state, national and international organizations, including the International Society for Heart Lung Transplantation, American College of Chest Physicians, Pulmonary Hypertension Association and the Ohio State Board of Hospitals. He is a past Associate Editor of Advances in Pulmonary Hypertension and reviewer for a number of international journals. He has been consistently named as “One of America’s Best Doctors” since 2005.
Featured Videos
Watch to find out more about this University Hospitals provider.
Patient Experience Reviews
Excellent experience as always
They are very prompt about everything
Very good expierence
Dr Shilz and staff are amazing. They have a way of combining professionalism, genuine caring and dispersement of information. They make you feel like you're their only patient. Simply the best!
Great health care provider
Top Knoch
Team is always kind and helpful.
Very good
I went to this provider with a lot of anxiety that something major was wrong. He took the time to thoroughly explain everything and help ease my anxiety
Dr. Schilz and his staff are terrific!
Dr Schilz is awesome and I an blessed to have him as my Pulmonologist. I couldn't be in better care!
In my opinion, Dr. Schilz is the most knowledgeable kind doctor I have seen in my 70 years of life I guess the good news is I won't need his assistance anymore but there's nobody better than him. He explains things on my level doesn't rush. You in a nutshell is the best.
Dr. Schilz is an amazing man. Caring, Smart and helped me tremendously.
*** is a tough illness, but having Dr. Schilz as my pulmonologist has really helped.
Related Blog Articles
Another Kind of High Blood Pressure: Pulmonary Hypertension
Most often caused by other diseases, pulmonary hypertension may be reversible, depending on the cause.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Robert Schilz disclosed the following Outside Relationships with Industry:
- - Gilead - Consulting
- - SCS Healthcare - Consulting
- - United Therapeutics Corp - Consulting
- - Actelion Ltd. - Honoraria
- - Bayer Corporation - Honoraria
- - Genentech, Inc. - Honoraria